Good Morning Good Morning.- Van you wake up to lick the smelly crack of Jimmy instead of heralding the arrival of Elite Traders Stock Champion!!!! It's official! I checked!! NOBODY DOES IT BETTER! I've done all > Show me one pick of yours over the same time-frame that has matched Jim's call on this one. The obvious take-away... Cramer was right. Case closed Stoney. Is what it is. ha ha ha show you one pick from 1998.!!!! I could give you a dozen from this year!!!!!!!! but I'll just give you the 1st name that popped in myhead. AND I DON'T HAVE TO GO BACK TO 98'; ha ha haha 2008 MELI @ $38.<------- If you want to waste your time searching I'll tell you from my memory I bought in somewhere in 2008 and it was mid to high $30's. I want to say $36 area and I posted here for sure-- MELI $36----------------------------> $950!!!!!!! CASE CLOSED I SMOKED CRAMER!!!! HE BARELY HAD A TRIPLE SOMETHING I GET ON EVEY BIOTECH LIKE IN THIS THREAD 3X WAKE UP VAN--- I'M YOUR MAN! hahahahahahahah
Kamada provides update on progress in Phase 3 trial of inhaled AAT KMDA Ionis Pharmaceuticals presents positive Phase 2 results in nephropathy IONS
--TreeHouse says FY23 revenue growth expected to be strong, cites pricing actions 07:07 THS The company said,… --TreeHouse sees Q4 continuing operations revenue up 22%-24%, consensus $1.43B 07:06 THS TreeHouse reports Q3 adjusted EPS 30c, consensus 16c 07:03 THS Reports Q3 revenue $1.3BM, consensus $1.29B. Net sales increased by 18% to $1.3B prior to divestiture. Continuing operations net sales increased 16.4% to $875M. "I'm proud of how we have successfully reshaped our business. Today we have greater strategic focus on accelerating our growth, improving operational efficiency and enhancing the value we deliver to our customers and consumers - all reflected in our recently unveiled statement of corporate purpose: to engage and delight - one customer at a time," said Steve Oakland, CEO and president. "The successful divestiture of a significant portion of our Meal Preparation assets positions us well to execute on our strategy: to capitalize on strong consumer demand trends in order to accelerate growth across our higher-margin private label snacking and beverage categories while driving long-term shareholder value."
--Ceragon Networks still sees 2023 revenue $325M-$345M, consensus $329.69M 07:05 CRNT Ceragon Networks reports Q3 non-GAAP EPS 5c, consensus 0c 07:03 CRNT Reports Q3 revenue $78.6M, consensus $78.48M. CEO Doron Arazi commented: "I'm pleased to report that in Q3, we achieved substantial success in key areas of our business, and made progress on our long-term strategy. Our bookings continued to reach record levels, including growing bookings in North America which are expected to yield high margins. Our focus on fulfillment led to growth in our Q3 revenues coupled with high gross margins. We continue to focus on the conversion of our high backlog to fulfill the growing demand from our customers. In parallel, we continue to see 5G network build-out pipelines, with CSPs and private networks both looking for cost-effective technologies for network upgrades and expanded services. Although the macro economy is unstable and risks associated with component shortages still exist, we are more confident with our long-term strategy and continue with its execution to capitalize on the opportunities ahead." --Bluebird Bio reports Q4 EPS (94c) vs, ($3.16) 07:04 BLUE Reports Q3 revenue $71K, consensus $1M.Cash Position: The Company's cash and cash equivalents and marketable securities balance was approximately $141 million as of September 30, 2022. In addition, the Company ended the quarter with $45 million in restricted cash. As a result of increased investment in current and upcoming launches, as well as post-marketing commitments related to the FDA approvals of ZYNTEGLO and SKYSONA, bluebird is adjusting its fourth quarter 2022 projected cash burn to between $75 million to $80 million. bluebird anticipates providing full year 2023 guidance early next year. "The third quarter officially launched bluebird bio as a commercial gene therapy company, following FDA approvals of ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy," said Andrew Obenshain, CEO bluebird bio. "Positive momentum continues to build through the ZYNTEGLO launch and we are on track to complete our first cell collection this quarter. Additionally, we are readying SKYSONA for commercial availability and are on track to file our biologics licensing application for lovo-cel for sickle cell disease in Q1 2023. As a result of milestones in the quarter, we are adjusting our fourth quarter 2022 financial guidance to account for post-marketing commitment expenses and increased investment in current and upcoming launches, which will enable the Company to fully benefit from its first-in-class position. Today, we are also very pleased to welcome Chris Krawtschuk as bluebird's next chief financial officer. Chris brings significant experience leading and advising financial and capital strategies for a multitude of commercial organizations and will play a critical role in our financing strategy and the evolution of bluebird's balance sheet as a commercial company."
Airbus initiated with a Buy at Redburn 06:49 EADSY, SAFRY Redburn analyst Oliver Brochet initiated coverage of Airbus (EADSY) with a Buy rating, calling it one of his preferred names within the aerospace and defense sector along with Safran (SAFRY). Supply chain constraints holding back production should fade across 2023 and both stocks offer material upside to current price levels, Brochet contends. More generally on the group, Brochet argues that further domestic European upside is limited for defense stocks, but growth from export markets may not be fully priced in. Ritchie Bros. reports Q3 adjusted EPS 53c, consensus 49c » 06:42 RBA Reports Q3 revenue… Ritchie Bros. to acquire IAA in stock, cash transaction valued at $7.3B 06:36 RBA, IAA Ritchie Bros. Fluor price target raised to $47 from $42 at Baird » 06:54 FLR Fluor upgraded to Buy from Neutral at DA Davidson 06:40 FLR DA Davidson analyst Brent Thielman upgraded Fluor to Buy from Neutral with a price target of $40, up from $25.
Palantir sees FY22 adjusted revenue $1.906B-$1.908B, consensus $1.89B 07:03 PLTR "We are raising our… Palantir reports Q3 adjusted EPS 1c, consensus 2c Albemarle price target raised to $325 from $305 at Deutsche Bank » 07:22 ALB Shift4 Payments reports Q3 adjusted EPS 44c, consensus 43c 07:21 FOUR Reports Q3 revenue… MacroGenics price target raised to $12 from $11 at H.C. Wainwright 06:16 MGNX H.C. Wai
First Watch Restaurant reports revenue $186.9M, consensus $180.74M 06:09 FWRG "We are very pleased with our Q3 results, which demonstrate our broad consumer appeal and the consistency and strength of our business model even in this uncertain economic environment," said CEO Chris Tomasso. "We believe our performance is among the best in our industry with the year-over-year increase in system-wide sales of 19.2%, same-restaurant sales growth of 12.0% and same-restaurant traffic growth of 3.7%. Our customers clearly recognize and appreciate the elevated dining experiences, differentiated offering and value proposition First Watch provides. Looking ahead, we continue to see a long runway for profitable growth as we invest in our people and accelerate our restaurant development." Choice Hotels reports Q3 EPS $1.85, consensus $1.69 06:05 CHH Reports Q3 revenue $414.27M, consensus $367.59M. "Our third quarter results and the acquisition of the Radisson Hotels Americas business are a significant leap forward in the evolution of both Choice Hotels' competitive position and future growth potential. For 11 consecutive quarters, our RevPAR growth has outperformed the hotel industry, confirming that our strategy of focusing our investments and growth on RevPAR accretive hotel segments and locations is working. Our future growth is now enhanced by the addition of the Radisson Hotels Americas' brands to our best-in-class business delivery engine. Radisson Hotels Americas is expected to provide the company with significant incremental recurring adjusted EBITDA upon its full integration in early 2024," said Patrick Pacious, president and chief executive officer, Choice Hotels. "We exceeded our 2019 earnings last year, have built on that strength through the third quarter this year and are confident that the changes we are observing in leisure and business travel behavior that favor our brands will enable us to maximize growth opportunities well into the future." Splunk initiated with an Outperform at Wolfe Research 06:02 SPLK
<<<<<<< a dozen ideas >>>>>>>>>>>> OPRA- DSP- GTBIF- IIPR- MGNX- TER- HRMY- RBT- OI- MACE- CCK- HLX- Other-))))))))))))))))))))))))))))))) PGRA- PrpertyGuru LIND- Linblad Exploration EE- Catchup Trade (nat gas) ESTA- Breasts (implants)
Wow they just said the Nazdog had it's worst week in the year last week... and GBA had our 3rd Best Week!!!! What Do I Tell You? Up Market / Down market It Don't Matter-with GBA!
POSSIBLE Gummies--> (A)Ionis Pharmaceuticals, Inc. (IONS) NasdaqGS - NasdaqGS 41.55-2.94(-6.61%) At close: 03:00PM EST 43.26+1.71(+4.12%)<------------- After hours:04:40PM EST (B)Shift4 Payments, Inc. (FOUR) NYSE - NYSE Delayed Price. 40.14-0.74(-1.81%) At close: 03:00PM EST 42.00+1.86(+4.63%)<----------- Pre-Market:07:31AM EST